Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYNK-001 in Recurrent Glioblastoma Multiforme
NCT04489420Phase 1Terminated
- Sponsor
- Celularity Inc.
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CYNK-001 in glioblastoma multiforme (GBM) (4 arms), sponsored by Celularity Inc. Primary endpoints: Dose-Limiting Toxicity at Day 42 and Adverse Events at 1 year. Started Oct 2020; status: terminated.
02
Drugs
CYNK-001
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT04489420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04489420.